Rochester, MN1 Active Studies

Paroxysmal Nocturnal Hemoglobinuria Clinical Trials in Rochester, MN

Find 1 actively recruiting paroxysmal nocturnal hemoglobinuria clinical trials in Rochester, MN. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
60
Enrolling

Recruiting Paroxysmal Nocturnal Hemoglobinuria Studies in Rochester

About Paroxysmal Nocturnal Hemoglobinuria Clinical Trials in Rochester

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disease where the immune system destroys red blood cells, causing dark-colored urine, fatigue, and blood clots. It is caused by a genetic mutation in blood stem cells. Treatment includes complement inhibitors like eculizumab.

There are currently 1 paroxysmal nocturnal hemoglobinuria clinical trials recruiting participants in Rochester, MN. These studies are seeking a combined 60 participants. Research is being sponsored by CRISPR Therapeutics AG. Clinical trial participation is free and participants receive study-related medical care at no cost.

Paroxysmal Nocturnal Hemoglobinuria Clinical Trials in Rochester — FAQ

Are there paroxysmal nocturnal hemoglobinuria clinical trials in Rochester?

Yes, there are 1 paroxysmal nocturnal hemoglobinuria clinical trials currently recruiting in Rochester, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What paroxysmal nocturnal hemoglobinuria treatments are being tested?

The 1 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for paroxysmal nocturnal hemoglobinuria.

Data updated October 15, 2026 from ClinicalTrials.gov